Skip to main content
Autobound logo

What Caris Life Sciences's latest 10-Q says: 10 signals

Caris Life Sciences filed its latest 10-Q with the SEC on Aug 5, 2026. It discusses automation investment, capex increase and debt refinancing.

Public (CAI)Biotechnology Research1,001 to 5,000 employeescarislifesciences.comLinkedIn

Filed
Aug 5, 2026
Filings
2
Signals
20

10-Q · latest 10

What Caris Life Sciences's 10-Q filings say

  1. 10-Q

    Filed · 10 signals

    SEC EDGAR

  2. 10-Q

    Filed · 10 signals

    SEC EDGAR

Showing 10 of 20 filing signals. The Signal API returns all of them.

Get them with one API call

Earnings calls

Caris Life Sciences earnings headlines

From earnings call transcripts (Signal API type earnings-transcripts).

Earnings call headlines
Call dateWhat the company said
Aggressively reinvesting profits into growth, R&D, sales, and marketingThe CFO explicitly stated the company will not 'hoard profits' and will increase spending to support major initiatives like whole genome sequencing for early detection and sales/marketing expansion. This signals significant available budget for technology, R&D tools, and GTM solutions.
Prioritizing reinvestment of profits into growth areas like early detection.Leadership explicitly stated their goal is not to 'hoard profits' but to reinvest strong cash flow into strategic initiatives, including R&D, sales, marketing, and assessing external opportunities. This indicates a strong appetite for new solutions and partnerships.
Actively assessing expansion of sales and marketing teams.With strong financial performance and a pipeline of new solutions, the CFO confirmed the company is evaluating an expansion of its go-to-market teams, signaling potential for near-term hiring and investment in sales and marketing infrastructure.
Achieved record Q3 revenue of $216.8M, up 113% year-over-year.Exceptional top-line growth and achieving net income for the first time provides significant financial flexibility for ongoing investment in new products, technology platforms, and market expansion.
Intensely focused on improving lab efficiencies and turnaround timesManagement celebrated achieving an 8-day turnaround for tissue and 7-day for blood tests, highlighting operational efficiency as a key priority amid growing volumes. This focus on speed and scale creates opportunities for lab automation, workflow optimization software, and process improvement solutions.
Gaining market share with Caris Assure liquid biopsy test, volume up 66%.The Caris Assure liquid biopsy product is experiencing accelerating growth, indicating successful market penetration and competitive wins. This success fuels further investment in the product line and commercial teams.

Signal API · MCP

Track Caris Life Sciences with the Signal API

One POST /v1/companies/enrich call with carislifesciences.com returns Caris Life Sciences 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.

Start Free1,000 free creditsUse it in Claude via MCP

2 credits per signal returned; zero-result calls are free. Endpoint reference

curl -X POST https://signals.autobound.ai/v1/companies/enrich \
  -H "X-API-KEY: $AUTOBOUND_API_KEY" \
  -H "Content-Type: application/json" \
  -d '{"domain":"carislifesciences.com","signal_types":["sec-10q"],"limit":20}'

Same industry

10-Q at related companies

Questions about Caris Life Sciences 10-Q

When did Caris Life Sciences file its latest 10-Q?
Caris Life Sciences filed its latest 10-Q on Aug 5, 2026. The one before it was filed on May 8, 2026.
What did Caris Life Sciences disclose in its latest 10-Q?
From the filing dated Aug 5, 2026: Caris Life Sciences funds major 2026 expansion with $400M loan and new Texas office.
What did Caris Life Sciences say on its recent earnings calls?
Q3 FY2025: Aggressively reinvesting profits into growth, R&D, sales, and marketing (dated Nov 5, 2025).
Where can I read Caris Life Sciences's 10-Q filing?
The full filing is on SEC EDGAR: https://www.sec.gov/Archives/edgar/data/2019410/000201941026000055/cai-20260630.htm. This page summarizes what the filing says and links to it.

Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.

Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.

Data as of .

How this data is built →Get it from the Signal API →